4 tracked superinvestors hold GILEAD SCIENCES INC (GILD), worth $4.0B combined, led by Team. Smart money is holding GILD as of the latest 13F filings.
Current price
$151.00
+37.4%
1Y
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it…
Market cap
$163.4B
P/E
16.15
Div yield
2.1%
Revenue YoY
2.4%
Analyst target
$151
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
4
tracked 13F / N-PORT funds
Combined value
$4.0B
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
0
1 buying · 1 selling
Smart money is holding GILD steady this quarter — buys and sells are balanced.
GILEAD SCIENCES INC (GILD) appears mainly in diversified and quant books here (4 funds, $4.0B combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Team at 1.9% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 1 added and 1 trimmed, a net add.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 1.9% | $2.2B | |
| Added | 0.9% | $1.4B | |
| Held | 0.4% | $280M | |
| Trimmed | 0.6% | $138M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
4 insiders filed SEC Form 144 for $14M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Anthony Welters | Director | 18,000 | $3M | 2026-08-26 |
| Jeffrey Bluestone | Director | 5,000 | $738K | 2026-08-20 |
| Johanna Mercier | Officer | 28,000 | $4M | 2026-08-17 |
| Daniel O'Day | Director & Officer | 55,000 | $7M | 2026-08-03 |
Which superinvestors own GILD?
4 tracked funds hold GILEAD SCIENCES INC (GILD), the largest being Team (Dodge & Cox Stock) at 1.9% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling GILD?
In the most recent 13F quarter, 1 tracked fund added or opened GILD and 1 trimmed it.
How much GILD do tracked funds hold?
Combined disclosed long exposure to GILD across tracked superinvestors is $4.0B as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.